



Neuren (NEU) – ASX Announcement

13 March 2023

Neuren investor webinar 9am AEDT Tuesday 14 March

Melbourne, Australia: Following the US FDA approval of DAYBUE™ (trofinetide), the first and only approved treatment for Rett syndrome, Neuren Pharmaceuticals Limited (ASX: NEU) will hold an investor webinar via Zoom at **9am AEDT on Tuesday 14 March 2023**.

Please click the link below to register for the presentation:

[RSVP for Zoom briefing](#)

Participants are invited to submit questions via the registration page or during the webinar.

About Neuren

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.

On 10 March 2023, the US Food and Drug Administration (FDA) approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an exclusive licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide in North America, while retaining all rights outside North America.

Neuren is conducting Phase 2 trials of its second drug candidate, NNZ-2591, for each of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.

Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

Contact:

Jon Pilcher, CEO: jpilcher@neurenpharma.com; +61 438 422 271

ASX Listing Rules information

This announcement was authorized to be given to the ASX by the board of directors of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.